CDSCO alerts reporting of falsified Defitelio drug if identified in India

India's central drug authority, CDSCO, has issued a public notice following a WHO alert concerning falsified DEFITELIO (defibrotide) 80 mg/ml concentrate for infusion, batch No. 24GC01A, expiring April 2027. Although this batch was never supplied to India and it has no marketing authorisation in India, healthcare professionals, hospitals, pharmacies and distributors should remain vigilant, verify product authenticity and immediately report any suspected stock found for sale or distribution to the relevant State/District Drugs Control Authority and CDSCO.

Join our 1500+ subscribers to get our daily Health Laws and Policy Updates.